Neurofibromatosis type 2 (NF2), an as-yet incurable disease that predispos es patients to multiple intracran ial and spinal tumors, requires a team approac h to treatment, because of its mul tisystem nature. Inclu ded on the team shou ld be neuro-otologists , neurosurgeons, ophthalmol ogists, geneticists, audi ologists, spee ch therapists and other rehabilitative personn el, including counselors, psychologists and, occasionally, psychiatrists.
Introduction
Neurofibromatosis type 2 (NF2) is a sys temic di sorder characterized by a genetically determined tendency. to produce multiple intracranial and spinal tumors, usually schwa nnomas, but also meningiomas, gliomas and ependymomas. As described in the article by Evans on page 97 of this issue of Ear, Nos e & Throat Journal, there is also a high probability of lens abnormalities in patients with NF2 . T he co ndition ex hibits a wide spectrum of biologic aggression, and a recent study indicates that the average survival from diagnosis to death is on ly 15 years.I Altho ugh NF2 cannot yet be cured, there are hopes that eventually molecular bio logic manipulation of the defect on chromosome 22 might lead to cure . No evidence ind icate s that such adva nces are imminent, however. Until gene therapy becomes a realistic proposition, clinicians are faced with a very difficult problem of clinical car e for patients with NF2 , for whom the presence of bil ateral vestibular schwannomas are the most comm on-but by no means the only or alway s the most pressing-problem.
Because of the multisystem nature of the di sorder, a team approach to therap y is most appropriate, with input from neuro-otologists, neurosur geon s, ophthalmologists, Departm geneticists, aud iologi sts , speech therapists and other rehabilitative personnel, including counselors, psyc ho logi sts and , occasionally , psyc hiatrists .i'The treat me nt plan must incl ude screening of re latives and genetic co unseling . The physician should be sensitive to the psychologica l impact of this potentially devastating disease on the patient and his or her family . Thi s impact is particularly marked in those families in which the di sorder appears for the first time as a new mutation , and parental anxieties and guilt feelings are common. Th e physician must ensure, as much as possible, that the patient is prep ared for the psychological blow of eventual tot al hearing loss and initiate appropriate training in non aud itory communication skills, when nece ssary .
Treatment Goals
Treatment options include obse rvation and cou nseling, radi oth erapy and surgery. In choosin g among these option s, the clinician should keep in mind the goa ls of the treatm ent plan :
1. Maximum preservation of life with a min imum of neurologic damage ; 2. Preservation of facia l nerve func tion; and 3. Preservation of useful hearing (see below).
The Dilemma
For the neuro-otologist, the di lemma in NF2 is to find the treatment strategy that preserves useful hearing and qu ality oflife for the longest time without undu ly increasing the risk of complications to the facial nerve or neurologic status. The factors that mu st be weighed in choosing the optimal strategy are complex. With the evolution of new er treatment mod aliti es, such as the gamma knife and the aud itory brainstem imp lant (ABI), the balance between the competing factors that determine the optimal strategy continues to chang e. Achieving thi s balance can be di fficult , since the morbidity associated with treatment can be mea sured in different dim en sions in view of the thre e goal s listed abo ve. A selected tre atment option might hav e a relatively low risk in one or more of these areas that is offset by a higher risk of poor outcome in anot her area.
T his balanc ing act is intrinsically difficult beca use it is 91
Hearing Preservation
Preservation of useful hearing remains one of the most difficult areas of mana gement of NF2, posing a number of dilemmas. The ideal to which one might theoretically aspire-namely, the total removal of both tumors with preservation of hearing in one or both ears-is rarely not easy to assign a relative value to any particular outco me. For instance, is a strategy offering 5% risk of facial paralysis with a 100 % risk of total hearing loss better than one offer ing a 10% risk of facia l paralysis and a 50% chance of hearing preservation-even if it were possible to reduce these probabilities to such a simplistic level?
To complicate matters further, the risks and outcomes of any particular option might be only partly realized at the . time of the treatment and partly realized month s or years after the treatment decision. For exa mple, conservative managem ent of a small tumor will increase the chances of preserving hearing longer but might increase the risks to the facial nerve if surgery is needed in the future.
Anoth er exampl e of the importance of this temporal factor conc erns the use of the gamm a knife , the exact role and effectiveness of which in the management of vestibular schwa nnoma are the subje ct of gre at interest and scrutiny. Although the incidence of hearin g loss with this modality is approximately 50%, it often occur s in a delayed fashion , thus giving more time for the learning of nonauditory meth ods of communication. On the other hand , previous irradiation with the gamma knife is at present seen as a contraindication to eve ntual treatment with the auditory brainstem implant.
Because of the complexity of these issues, NF2 treatment requires experience and j udgment that might only be available at a larger referra l ce nter. The number of parameters that have to be taken into consideration in formulating a treatment plan means that each patient ' s treatment must be individ ualized while remai ning flexible and react ive.
Some of the factors that must be considere d includ e the phenotype, the status of hearing in each ear , tumor size and the chance s of hearin g preservation. These factors , in turn , are influ enced by additional factors uniqu e to each tumor, as well as by the surgical team ' s level of experience and experti se, ease of access to the gamma knife and to auditory brain stem implants, and the opinions and wishes of the patient and patient's family.
The primary goal of management is always to avoid or anticipate life-threatening developm ent s. Careful regular clini cal assessment coupl ed with magnetic resonan ce imaging (MRI) of the neur al axis might warn of impending complications and suggest when surgery is indicated. The approach to surgery should be based on a minimal interventionist philosoph y. It might be that intracranial surgery is indicated if there is evidence of brain stem compression or elevated intracranial pressure. The mere presence of tumor in the posterior fossa, however, is not --------------------------, an indica tion for surge ry. If surgery is deemed necessary, total tumor removal should not always be seen as the essential objective. Avoidance of neurologic damage is more important in a cond ition such as NF2, in which there is high likelihood of new tumors grow ing in the same location anyway. A similar approach is recommended in the handlin g of spinal tum ors, and it is often the case that management of spin al lesions takes precedence over the intracrani al condition.
The psychological effect of facial paraly sis is well known to otologists. The importance of avoiding facial nerve damage is greatly heightened in NF2 because of the presence of bilateral tumo rs and the terrible burden of bilateral facial weakness. One must con sider the potenti al threat to vision, posed by loss of tearin g and the blink reflex. Also, the eyes might already have redu ced sensation because of trigeminal nerve involvement by a vestibular schwannom a or a separate trigeminal tumor and might, furthermore, be comprom ised by posteri or lens opacities. In keepin g with the minimal interve ntionist philosophy menti oned earl ier, heroic efforts should not be made to remove every last frag ment of tumor from the facial nerve during surgery, if in doing so one increases the risk of compro mising facial function.
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., . , Medical Systems achievable and in many instances might not necessarily be appropriate. With sporadic unilateral vestibular schwannomas, hearing-preservation surgery is not usually considered unless useful hearing is present, especially since the safest route for facial nerve preservation is the translabyrinthine approach. What constitutes useful hearing remains, however, controversial. An interaural pure tone audiometric average difference of 30 dB with a maximum speech discrimination score of 50% in the tumor ear are the minimum criteria, but many surgeons set tighter limits of30 dB and 70%, respectively.' In contrast, in NF2 any residual and amplifiable hearing is considered useful when set against the possibility of total bilateral deafness.
In NF2 there are unique anatomic and histologic factors to consider that, in theory and practice, make successful hearing preservation a difficult goal to attain . NF2 tumors, although usually arising on the vestibular division of the vestibulocochlear nerve, have a propensity to invade the cochlear nerve so that the plane of surgical separation between the tumor and the cochlear nerve is often impossible to define. In addition, NF2 tumors are often multicentric in nature and might envelope the cochlear nerve, so that in effect the nerve fibers appear to run through the tumor.r" In that situation an intracapsular subtotal removal with the aim of hearing preservation would have a high likelihood of failure .
Clinical Management Problems
NF2 is associated with varying clinical presentations that must be considered. For example, if there is a large tumor with poor hearing on one side and a small tumor with good hearing on the opposite side, the decision is easy : remove the large tumor via a translabyrinthine approach. If the situation is reversed, however, with a large tumor with good hearing on one side and a small tumor with no hearing on the opposite side, what should one do? Clearly the large tumor with good hearing should be retained until the hearing is lost naturally (in which case there is no point in not removing the tumor) or until its removal becomes a neurosurgical necessity regardless of the hearing level. Subtotal removal remains an option but, for the reasons outlined above, might well be unsuccessful. A case could be made, however, for removal of the small tumor with no hearing at an early stage, so that the cochlear nerve could be retained and with it the possibility of an eventual cochlear implant. This strategy has been employed by the authors. Cochlear implantation in such a situation has been successfully performed.PBetween these two extreme examples fall the large proportion of NF2 sufferers, and here the experience of the team and the need for individualized treatment is paramount.
Consider the situation of bilateral small tumors « 1 ern intracranial diameter) with good hearing. There is not . universal agreement as to the best strategy in this situation. Nowhere is this better demonstrated than in the 94 conflicting advice from the National Institutes of Health . The NIH Consensus Development Statement of 1987 suggested "Because the possibility of removing tumor with minimal injury to the auditory nerve is much greater when the tumor is small, consideration should be given to attempting to remove one progressive tumor while bilateral hearing remains . If the tumor is successfully removed with preservation of hearing on that side, consideration should be given to removing the second tumor.YWithin 2 years , however, the NIH had modified its recommendations to: "The mere presence of an acoustic neuroma in a patient with neurofibromatosis 2 is not an indication for its surgical removal; these tumors might not change for years, particularly in men . . . .Watchful waiting is prudent for neurologically stable cases."!" The policy adopted by the authors in the University of Manchester program is to recommend removal of the more favorable tumor through a middle cranial fossa approach, after discussing all the treatment options with the patient. The most important favo rable pointers are tumor size and the degree of lateral extension in the internal meatus, as determined on T2-weighted MRI. The hope is that hearing will be preserved but if it is not, that the cochlear nerve will be preserved and will eventually be capable of taking a multichannel cochlear implant. If hearing is preserved a similar procedure will be offered on the opposite side.
Stereotactic Radiosurgery
Stereotactic radiosurgery (the gamma knife) has in recent years come to the fore as a suggested alternative to microsurgical removal in the management of vestibular schwannomas.vFlt delivers a single, precisely targeted dose of ionizing radiation to the tumor. The steep dose gradient is said to minimize damage to adjacent structures, such as the cochlea and the facial and cochlear nerves. The main advantages of this treatment are obvious: avoidance of an operation, a short hospital stay and no period of convalescence. There are, however, several real objections to this treatment modality.
For most tumors the best that is usually claimed for radiosurgery is "tumor control" or arrest of growth, rather than tumor eradication. It requires a very long period of follow-up, with repeat scanning, to ascertain whether that control is permanent, and at present such follow-up data are not available. Furthermore there is significant morbidity to the hearing, both immediately and over time, and to the facial and trigeminal nerves. 13 There is a reported risk of hydrocephalus,14and a fear of inducing malignant change in a hitherto benign tumor. For these reasons most clinicians who manage vestibular schwannoma patients remain cautious about recommending treatment with the gamma knife, but await further developments with interest.
The gamma knife might have a role in the management ofNF2, perhaps in the case of a growing tumor in the only hearing ear, or in patients unfit for conventional microsur-* For susceptible strains of indocated organisms.
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The current state of this exciting new developm ent is descr ibed in the article by Laszig and coworkers (page 110 of this issue of Ear, Nose & Throat Journal).
